Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
PP&E Net
Nektar Therapeutics
PP&E Net Peer Comparison
Competitive PP&E Net Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
PP&E Net
$34.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-7%
|
|
Johnson & Johnson
NYSE:JNJ
|
PP&E Net
$19.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
PP&E Net
$8.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
PP&E Net
$18.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
Merck & Co Inc
NYSE:MRK
|
PP&E Net
$23B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
PP&E Net
$13.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
See Also
What is Nektar Therapeutics's PP&E Net?
PP&E Net
34.7m
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's PP&E Net amounts to 34.7m USD.
What is Nektar Therapeutics's PP&E Net growth rate?
PP&E Net CAGR 10Y
-7%
Over the last year, the PP&E Net growth was -50%. The average annual PP&E Net growth rates for Nektar Therapeutics have been -43% over the past three years , -24% over the past five years , and -7% over the past ten years .